OBJECTIVE: To estimate the long-term absolute risk for cardiovascular disease (CVD) according to fasting glucose (FG) levels below the threshold of diabetes. RESEARCH DESIGN AND METHODS: We pooled data from seven observational cohorts of U.S. black and white men and women followed from 1960 to 2015. We categorized FG as follows: <5.0, 5.0-5.5, 5.6-6.2, 6.3-6.9 mmol/L, and diabetes (FG ≥7.0 mmol/L or use of diabetes medications). CVD was defined as fatal/nonfatal coronary heart disease and fatal/nonfatal stroke. We estimated the risk of CVD by FG category at index age 55 years using a modified Kaplan-Meier survival analysis, adjusted for the competing risk of non-CVD death. We also assessed risk for incident CVD according to change in FG before 50 years of age, specifically among the categories <5.6 mmol/L, 5.6-6.9 mmol/L, and diabetes. RESULTS: Our sample included 19,630 individuals (6,197 blacks and 11,015 women) without a prior CVD event. Risk for CVD through 85 years of age ranged from 15.3% (<5.0 mmol/L) to 38.6% (diabetes levels) among women and from 21.5% (5.0-5.5 mmol/L) to 47.7% (diabetes levels) among men. An FG of 6.3-6.9 mmol/L was associated with higher long-term CVD risk compared with the lowest FG among men but not women. Increases in glucose during midlife with conversion to diabetes were associated with higher cardiovascular risk (1.3- to 3.6-fold) than increases in glucose below the diabetes threshold. CONCLUSIONS: Middle-age individuals with diabetes have high long-term absolute risk for CVD. These data strongly support the importance of blood glucose monitoring in midlife for CVD prevention.
OBJECTIVE: To estimate the long-term absolute risk for cardiovascular disease (CVD) according to fasting glucose (FG) levels below the threshold of diabetes. RESEARCH DESIGN AND METHODS: We pooled data from seven observational cohorts of U.S. black and white men and women followed from 1960 to 2015. We categorized FG as follows: <5.0, 5.0-5.5, 5.6-6.2, 6.3-6.9 mmol/L, and diabetes (FG ≥7.0 mmol/L or use of diabetes medications). CVD was defined as fatal/nonfatal coronary heart disease and fatal/nonfatal stroke. We estimated the risk of CVD by FG category at index age 55 years using a modified Kaplan-Meier survival analysis, adjusted for the competing risk of non-CVD death. We also assessed risk for incident CVD according to change in FG before 50 years of age, specifically among the categories <5.6 mmol/L, 5.6-6.9 mmol/L, and diabetes. RESULTS: Our sample included 19,630 individuals (6,197 blacks and 11,015 women) without a prior CVD event. Risk for CVD through 85 years of age ranged from 15.3% (<5.0 mmol/L) to 38.6% (diabetes levels) among women and from 21.5% (5.0-5.5 mmol/L) to 47.7% (diabetes levels) among men. An FG of 6.3-6.9 mmol/L was associated with higher long-term CVD risk compared with the lowest FG among men but not women. Increases in glucose during midlife with conversion to diabetes were associated with higher cardiovascular risk (1.3- to 3.6-fold) than increases in glucose below the diabetes threshold. CONCLUSIONS: Middle-age individuals with diabetes have high long-term absolute risk for CVD. These data strongly support the importance of blood glucose monitoring in midlife for CVD prevention.
Authors: Jarett D Berry; Alan Dyer; Xuan Cai; Daniel B Garside; Hongyan Ning; Avis Thomas; Philip Greenland; Linda Van Horn; Russell P Tracy; Donald M Lloyd-Jones Journal: N Engl J Med Date: 2012-01-26 Impact factor: 91.245
Authors: Kirsten Bibbins-Domingo; Mark J Pletcher; Feng Lin; Eric Vittinghoff; Julius M Gardin; Alexander Arynchyn; Cora E Lewis; O Dale Williams; Stephen B Hulley Journal: N Engl J Med Date: 2009-03-19 Impact factor: 91.245
Authors: A R Folsom; D R Jacobs; L E Wagenknecht; S P Winkhart; C Yunis; J E Hilner; P J Savage; D E Smith; J M Flack Journal: Am J Epidemiol Date: 1996-08-01 Impact factor: 4.897
Authors: Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss Journal: N Engl J Med Date: 2014-04-17 Impact factor: 91.245
Authors: EunSeok Cha; Francisco J Pasquel; Fengxia Yan; David R Jacobs; Sandra B Dunbar; Guillermo Umpierrez; Yuni Choi; James M Shikany; Michael P Bancks; Jared P Reis; Melissa Spezia Faulkner Journal: Diabetes Res Clin Pract Date: 2021-11-11 Impact factor: 5.602
Authors: J Henny; R Nadif; S Le Got; S Lemonnier; A Ozguler; F Ruiz; K Beaumont; D Brault; E Sandt; M Goldberg; M Zins Journal: Front Public Health Date: 2020-12-10
Authors: Arjun Sinha; Hongyan Ning; Faraz S Ahmad; Michael P Bancks; Mercedes R Carnethon; Matthew J O'Brien; Norrina B Allen; John T Wilkins; Donald M Lloyd-Jones; Sadiya S Khan Journal: Cardiovasc Diabetol Date: 2021-03-22 Impact factor: 8.949
Authors: Adam J Nelson; Emily C O'Brien; Lisa A Kaltenbach; Jennifer B Green; Renato D Lopes; Caryn G Morse; Hussein R Al-Khalidi; Vanita R Aroda; Matthew A Cavender; Tanya Gaynor; Julienne K Kirk; Ildiko Lingvay; Melissa L Magwire; Darren K McGuire; Jonathan Pak; Rodica Pop-Busui; Caroline R Richardson; Cagri Senyucel; Michelle D Kelsey; Neha J Pagidipati; Christopher B Granger Journal: JAMA Netw Open Date: 2022-02-01
Authors: Nunzio Camerlingo; Martina Vettoretti; Andrea Facchinetti; Giovanni Sparacino; Julia K Mader; Pratik Choudhary; Simone Del Favero Journal: Sci Rep Date: 2020-10-23 Impact factor: 4.379